Korn JH. Pathogenesis of systemic sclerosis. Arthritis and allied conditions. 2001:1643-54.

Block JA, Sequeira W. Raynaud's phenomenon. Lancet. 2001;357:2042-8.

Desai R, Korn JH. Diagnosis and management of Raynaud phenomenon. J Musculoskel Med.. 2003;20:124-35.

LeRoy EC, Black C, Fleischmajer R. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol.. 1988;15:202-5.

Jimebez AS, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med.. 2004;140:37-50.

Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum.. 1975;4:351-68.

Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the endothelial cell. Hypertension. 1988;12:530-48.

Inoue A, Yanagisawa M, Kimura S. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA.. 1989;86:2863-7.

Biondi ML, Marasini B, Bassani C, Agostoni A. Increased plasma endothelin levels in patients with Raynaud's phenomenon. N Engl J Med.. 1991;324:1139-40.

Rubin LJ, Badesch DB, Barst RJ. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med.. 2002;346:896-903.

Sitbon O, Badesch DB, Channick RN. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003;124:247-54.

Korn JH, Mayes M, Matucci Cerinic M. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum.. 2004;50:3985-93.

Seibold JR, Matucci-Cerinic M, Denton CP. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis.. 2006;65(^sII):S90.